Impact Biomedical Quick Ratio (IBO) starting from the third quarter 2026 to third quarter 2025, Financial Strength Trends, Rankings, Financial Ratios - CSIMarket
CSIMarket Company Name, Ticker, Competitors, else..
 


• Quick Ratio
• Working Capital
• LT Debt to Equity
• Debt to Equity
• Leverage Ratio
• Tangible Leverage
• Interest Coverage
• Debt Coverage
• Work. Cap. Per Revenue
IMPACT BIOMEDICAL INC.  (NYSE: IBO)

Impact Biomedical's Quick Ratio

IBO's quarterly Quick Ratio and Cash & cash equivalent, Current Liabilities growth


Impact Biomedical's Cash & cash equivalent grew by 110 % in the Q3 2026 sequentially, faster than Current Liabilities, this led to improvement in Impact Biomedical's Quick Ratio to 0.01, Quick Ratio remained below IMPACT BIOMEDICAL INC. average.

Within Major Pharmaceutical Preparations industry IMPACT BIOMEDICAL INC. booked the highest Quick Ratio than Impact Biomedical in the third quarter 2026. While total ranking remained the same in the Q3 2026 compared to the second quarter 2026 at no. 14.

Explain Quick Ratio?
How much Cash & cash equivalents IBO´s has?
What are IBO´s Current Liabilities?



Download as CSV
Commercial Data Licensing & OEM
Annual commercial subscriptions for corporate use, internal BI systems, management reporting, AI integration, and client-facing platforms
API & Data Feeds
Programmatic access to normalized fundamentals & ratios.

API endpoints for this dataset

https://api.csimarket.com/api/v1/companies/IBO/financial-strength
https://api.csimarket.com/api/v1/companies/IBO/fundamentals
https://api.csimarket.com/api/v1/companies/IBO/fundamentals?mode=as_of&as_of=YYYY-MM-DD
Programmatic access for models, analytics, and integration workflows.
Explore the Financial Data API
Financial API Point-in-Time Financial Fundamentals API API Server API Docs API Discovery
Connect Your AI Assistant
How to Connect Your AI Assistant to CSIMarket MCP MCP Server
Access this full dataset via API
Free sample Full docs All endpoints
IBO Quick Ratio (Sep 30 2026)
Q3		 (Jun 30 2026)
Q2 		(Mar 31 2026)
Q1 		(Dec 31 2025)
Q4 		(Sep 30 2025)
Q3
Y / Y Current Liabilities Change -90.03 %
Y / Y Cash & cash equivalent Change 75 %
Quick Ratio MRQ 0.01
IBO's Total Ranking # 14
Seq. Current Liabilities Change 16.04 %
Seq. Cash & cash equivalent Change 110 %



Quick Ratio third quarter 2026 Company Ranking
Within: No.
Major Pharmaceutical Preparations Industry # 1
Healthcare Sector # 1
Overall Market # 14


Quick Ratio Statistics
High Average Low
2.34 0.2 0
(Sep 30 2024)   (Jun 30 2024)




Financial Statements
Impact Biomedical's Current Liabilities $ 2 Millions Visit IBO's Balance sheet
Impact Biomedical's Cash & cash equivalent $ 0 Millions Visit IBO's Balance sheet
Source of IBO's Sales Visit IBO's Sales by Geography


Cumulative Impact Biomedical's Quick Ratio

IBO's Quick Ratio for the trailling 12 Months

IBO Quick Ratio

 (Sep 30 2026)
12 Months		 (Jun 30 2026)
12 Months 		(Mar 31 2026)
12 Months 		(Dec 31 2025)
12 Months 		(Sep 30 2025)
12 Months
Y / Y Current Liabilities TTM Growth -91.64 %
Y / Y Cash & cash equivalent TTM Growth -98.63 %
Quick Ratio TTM 0.01
Total Ranking TTM # 3963
Seq. Current Liabilities TTM Growth -79.44 %
Seq. Cash & cash equivalent TTM Growth 20 %

Quick ratio ranking by company, industry and sector >> Back to IBO Financial Strength Comparisons >> Go to Compare IBO Quick Ratio to its Competitors

On the trailing twelve months basis IBO Cash & cash equivalent soared by 75 % in Q3 2026 year on year, while Current Liabilities increased to $2 millions, this led to